

2022 ASH Annual Meeting
Northside Blood and Marrow/Leukemia /Immunotherapy Program and Collaborative Oral and Poster Presentations

TOTAL N = 15

Program Oral Presentation N = 1, Collaborative Oral Presentations N = 2, Program Poster Presentations N = 7 and Collaborative Poster Presentations N = 5

Program Oral Presentation: N = 1

491 Phase II Study of PD-1 Blockade Following Fludarabine/Melphalan-Based Autologous Transplantation for Acute Myeloid Leukemia Patients Ineligible for Allogeneic Transplant

Scott R. Solomon, MD¹, Melhem Solh, MD¹, Lawrence E. Morris Jr., MD^{1*}, H. Kent Holland, MD¹, Lizamarie Bachier-Rodriguez, MD^{1*}, Xu Zhang, PhD^{2*}, Caitlin Guzowski^{1*}, Katelin C Jackson^{1*}, Stacey Brown, CCRP^{1*} and Asad Bashey, MD, PhD¹

¹Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA

²Center for Clinical and Transitional Sciences, University of Texas Health Science Center, Houston, TX

Collaborative Oral Presentations: N = 2

158 Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Noopur Raje, MD¹, Nizar Jacques Bahlis, MD², Caitlin Costello, MD³, Bhagirathbhai Dholaria, MBBS⁴, **Melhem Solh, MD⁵**, Moshe Yair Levy, MD⁶, Michael H Tomasson, MD^{7*}, Michael A. Damore, PhD^{8*}, Siboj Jiang, PhD^{9*}, Cynthia Basu, PhD^{10*}, Athanasia Skoura, PhD^{11*}, Edward M Chan, MD^{12*}, Suzanne Trudel¹³, Andrzej Jakubowiak, MD, PhD^{14*}, Michael P Chu, MD^{15*}, Cristina J. Gasparetto, MD¹⁶, Andrew P. Dalovisio, MD¹⁷, Michael Sebag, MD, PhD¹⁸ and Alexander M Lesokhin, MD¹⁹

¹Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, ²Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada, ³Moore's Cancer Center, University of California San Diego, La Jolla, CA, ⁴Vanderbilt University Medical Center and Vanderbilt- Ingram Cancer Center, Nashville, TN, ⁵Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA

⁶Department of Medical Oncology, Baylor Scott and White Health, Dallas, TX, ⁷Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, ⁸Oncology Research and Development, Pfizer, San Diego, CA

⁹Early Clinical Development, Pfizer Inc, San Diego, CA, ¹⁰Early Clinical Development, Pfizer, San Diego, CA

¹¹Early Clinical Development, Pfizer, Collegeville, PA, ¹²Oncology Research and Development, Pfizer, South San Francisco, CA, ¹³Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

¹⁴Department of Medicine, University of Chicago Medical Center, Chicago, IL, ¹⁵Cross Cancer Institute, Edmonton, AB, Canada, ¹⁶Department of Medicine, Duke University Cancer Institute, Durham, NC

¹⁷Department of Hematology and Oncology, Ochsner Health, Jefferson, LA, ¹⁸Cedars Cancer Center, McGill

2022 ASH Annual Meeting
Northside Blood and Marrow/Leukemia /Immunotherapy Program and Collaborative Oral and Poster Presentations

Collaborative Oral Presentations: con't

University Health Centre, Montreal, QC, Canada, ¹⁹Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, NY

655 Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study

Jeremy S. Abramson, MD¹, Scott R. Solomon, MD², Jon E. Arnason, MD³, Patrick B. Johnston, MD, PhD⁴, Bertram Glass, MD⁵, Veronika Bachanova, MD, PhD⁶, Sami Ibrahim, MD⁷, Stephan Mielke, MD⁸, Pim Mutsaers, MD⁹, Francisco Hernandez-Ilizaliturri, MD¹⁰, Koji Izutsu¹¹, Franck Morschhauser, MD, PhD¹², Matthew A. Lunning, DO, FACP¹³, Alessandro Crotta, MD¹⁴, Sandrine Montheard, MS¹⁴, Alessandro Previtali, MSc¹⁴ and Manali Kamdar, MD, MBBS¹⁵¹Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, ²Northside Hospital Cancer Institute, Atlanta, GA, ³Hematologic Malignancy and Bone Marrow Transplantation Program, Beth Israel Deaconess Medical Center, Boston, MA, ⁴Mayo Clinic, Rochester, ⁵Helios Klinikum Berlin-Buch, Berlin, Germany, ⁶Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, ⁷University of Oklahoma Stephenson Cancer Center, Oklahoma City, ⁸Karolinska Institutet and University Hospital, Karolinska Comprehensive Cancer Center, Stockholm, Sweden, ⁹Erasmus University Medical Center, Rotterdam, Netherlands, ¹⁰Roswell Park Comprehensive Cancer Center, Buffalo, NY ¹¹National Cancer Center Hospital, Tokyo, Japan, ¹²Centre Hospitalier Universitaire de Lille. Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France, ¹³University of Nebraska, Omaha, NE, ¹⁴Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland, ¹⁵University of Colorado Cancer Center, Aurora

2022 ASH Annual Meeting
Northside Blood and Marrow/Leukemia /Immunotherapy Program and Collaborative Oral and Poster Presentations

Program Poster Presentations: N = 7

2070 Differences in Patterns of Infections Among Allogeneic Hematopoietic Cell Transplant Patients Receiving Letermovir Prophylaxis for Cytomegalovirus

Melhem Solh, MD¹, Scott R. Solomon, MD¹, Xu Zhang, PhD^{2*}, Lawrence E. Morris Jr., MD^{1*}, Lizamarie Bachier-Rodriguez, MD^{1*}, H. Kent Holland, MD¹ and Asad Bashey, MD, PhD¹

¹Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA, ²Center for Clinical and Transitional Sciences, University of Texas Health Science Center, Houston, TX

2120 Selecting the Best Transplant Donor (HLA-Matched vs. Haploidentical) for Patients with Lymphoid Malignancy Based on Recipient HLA-B-Leader Genotype

Scott R. Solomon, MD¹, Lizamarie Bachier-Rodriguez, MD^{1*}, Xu Zhang, PhD^{2*}, Michael T Aubrey^{3*}, Christina L Roark^{3*}, Lawrence E. Morris Jr., MD^{1*}, H. Kent Holland, MD¹, Asad Bashey, MD, PhD¹ and Melhem Solh, MD¹

¹Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA, ²Center for Clinical and Transitional Sciences, University of Texas Health Science Center, Houston, TX, ³University of Colorado Cord Blood Bank & Clinimmune Laboratory, Aurora, CO

3368 Frequency and Clinical Significance of Mixed T-Cell Chimerism Following Myeloablative Busulfan and Cyclophosphamide Conditioning in HLA -Matched Donor Transplants for Myeloid Malignancies: An Analysis of 179 Patients Transplanted at a Single Center

Asad Bashey, MD, PhD¹, Xu Zhang, PhD^{2*}, Scott R. Solomon, MD¹, Lizamarie Bachier-Rodriguez, MD^{1*}, H. Kent Holland, MD¹, Lawrence E. Morris Jr., MD^{1*} and Melhem Solh, MD¹

¹Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, ²Center for Clinical and Transitional Sciences, University of Texas Health Science Center, Houston, TX

3404 Effect of CMV Reactivation and Letermovir Use on Chronic Gvhd Incidence Following Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide

Scott R. Solomon, MD¹, Lizamarie Bachier-Rodriguez, MD^{1*}, Xu Zhang, PhD^{2*}, H. Kent Holland, MD¹, Lawrence E. Morris Jr., MD^{1*}, Asad Bashey, MD, PhD¹ and Melhem Solh, MD¹

¹Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA, ²Center for Clinical and Transitional Sciences, University of Texas Health Science Center, Houston, TX

2022 ASH Annual Meeting

Northside Blood and Marrow/Leukemia /Immunotherapy Program and Collaborative Oral and Poster Presentations

Program Poster Presentations: con't

3444 HLA Evolutionary Divergence (HED) Informs the Effect of HLA-B-Loci Mismatch on Relapse and Disease Free Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)

Melhem Solh, MD¹, Michael T Aubrey^{2*}, Xu Zhang, PhD^{3*}, Asad Bashey, MD, PhD¹, Brian M Freed^{2*}, Christina L Roark^{2*}, Lizamarie Bachier-Rodriguez, MD^{1*}, Lawrence E. Morris Jr., MD^{1*}, H. Kent Holland, MD¹ and Scott R. Solomon, MD¹

¹Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA,²University of Colorado Cord Blood Bank & Clinimmune Laboratory, Aurora, CO,³Center for Clinical and Transitional Sciences, University of Texas Health Science Center, Houston, TX

4763 TBI-Based Myeloablative Conditioning Prior to Haploidentical Versus Matched Donor Transplantation for Acute Lymphoblastic Leukemia

Scott R. Solomon, MD¹, Lizamarie Bachier-Rodriguez, MD^{1*}, Xu Zhang, PhD^{2*}, Asad Bashey, MD, PhD¹, Lawrence E. Morris Jr., MD^{1*}, H. Kent Holland, MD¹ and Melhem Solh, MD¹

¹Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA,²Center for Clinical and Transitional Sciences, University of Texas Health Science Center, Houston, TX

4944 Transition from Initial Therapy to Hematopoietic Cell Transplantation for Non-Favorable Risk Acute Leukemia and MDS Patients in the Era of Haploidentical Donor Availability: Assessment of Efficacy, Barriers and Racial Disparities in 269 Consecutive Patients Treated in an Integrated Leukemia/HCT Program

Asad Bashey, MD, PhD¹, Xu Zhang, PhD^{2*}, Melhem Solh, MD¹, H. Kent Holland, MD¹, Lawrence E. Morris Jr., MD^{1*}, Lizamarie Bachier-Rodriguez, MD^{1*} and Scott R. Solomon, MD¹

¹Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA,²Center for Clinical and Transitional Sciences, University of Texas Health Science Center, Houston, TX

2022 ASH Annual Meeting

Northside Blood and Marrow/Leukemia /Immunotherapy Program and Collaborative Oral and Poster Presentations

Collaborative Post Presentations: N = 5

2005 Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma

Caron A. Jacobson, MD¹, Tilanthi Jayawardena, PhD², Lou Yu, MS³, Jason Hallman², Robert Schmittling², Erin Cuneo², Ian Belle, PhD², Gavin Sampey, PhD², Danica Cabral², Ashleigh Derrick², Josie Tueller², Koen Van Besien, MD, PhD^{4,5}, **Scott R. Solomon, MD^{6,7}**, Adam J. Olszewski, MD^{8,9}, Joseph E. Maakaron, MD^{10,11}, Ran Reshef, MD, MSc^{12,13}, Anthony S. Stein, MD¹⁴, Abhinav Deol, MD¹⁵, Nitin Jain, MD¹⁶, Alan F. List, MD² and Bijal D. Shah, MD^{17,18}

¹Dana-Farber Cancer Institute, Boston, MA, ²Precision BioSciences, Inc., Durham, NC, ³Clinical Operations, Precision BioSciences, Inc., Durham, NC, ⁴Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, ⁵Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, ⁶Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, ⁷Blood and Marrow Transplant Program, BMT Group of Georgia, Atlanta, GA, ⁸Division of Hematology/Oncology, Brown University, Providence, RI, ⁹Rhode Island Hospital, Providence, RI

¹⁰Division of Hematology, Oncology and Transplantation, University of Minnesota Medical Center, Minneapolis, MN, ¹¹Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

¹²Columbia Center for Translational Immunology, New York, NY, ¹³Blood and Marrow Transplantation Program, Columbia University, New York, NY, ¹⁴Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, CA, ¹⁵Department of Oncology, Wayne State University/ Karmanos Cancer Institute, Detroit, MI, ¹⁶Department of Leukemia, MD Anderson Cancer Center, Houston, TX, ¹⁷H. Lee Moffitt Cancer Center, Tampa, FL, ¹⁸Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

2771 CDK 8/19 Kinase Inhibitor RVU120 in Patients with AML or Higher-Risk MDS: Safety and Efficacy Results from New Dose Escalation Cohorts

Camille Abboud Sr., MD¹, Jan Maciej Zaucha, MD², **Scott R. Solomon, MD³**, Terrence Bradley, MD⁴, Elie Mouhayar, MD⁵, Noemi Angelosanto, MD⁶, Hendrik Nogai, MD⁶, Renata Dudziak, MD⁷, Tomasz Rzymyski, PhD⁶, Peter Littlewood, BSc⁸, Krzysztof Brzózka, PhD⁶, Axel Glasmacher, MD⁹, Gautam Borthakur, MD¹⁰, Howard A. Burris Sr., MD¹¹ and Ewa Lech Marańda, MD, PhD¹²

¹Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO

²Early Phase Clinical Trial Unit, University Clinical Center, Gdansk, Poland, ³Leukemia Program, Northside Hospital Cancer Center Institute, Atlanta, GA, ⁴University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, ⁵MDACC, Houston, TX, ⁶Ryvu Therapeutics, Cracow, Poland, ⁷Ryvu Therapeutics, Kraków, Poland, ⁸Ryvu Therapeutics, Krakow, Poland, ⁹Dep. of Internal Medicine III, University Clinic Bonn, Bonn, Germany

2022 ASH Annual Meeting
Northside Blood and Marrow/Leukemia /Immunotherapy Program and Collaborative Oral and Poster Presentations

Collaborative Post Presentations: con't

¹⁰Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, ¹¹Sarah Cannon Research Institute, Nashville, TN, ¹²Institute of Hematology and Transfusion Medicine, Warsaw, Poland

2960 Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial

Juan Pablo Alderuccio, MD¹, Russ A Kuker, MD², Isildinha M Reis, PhD³, Muthiah Nachiappan, MD⁴, Brad S. Kahl, MD⁵, Mehdi Hamadani, MD⁶, Weiyun Z. Ai, MD, PhD⁷, John Radford, MD, FRCPATH, FMedSci⁸, **Melhem Solh, MD⁹**, Kirit M. Ardeshta¹⁰, Brian T. Hess, MD¹¹, Matthew A. Lunning, DO, FACP¹², Pier Luigi Zinzani, MD, PhD¹³, Anastasios Stathis, MD¹⁴, Carmelo Carlo-Stella, MD, PhD¹⁵, Eric Yu, PhD¹⁶, Paolo F Caimi, MD^{17,18}, Deukwoo Kwon, PhD¹⁹, Izidore S. Lossos, MD²⁰, Fei Yang, PhD²¹ and Craig H. Moskowitz, MD²²

¹Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, ²Division of Nuclear Medicine, University of Miami Miller School of Medicine, Miami, ³Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, ⁴Division of Nuclear Medicine, Sylvester Comprehensive Cancer Center, Miami, ⁵Division of Oncology, Washington University School of Medicine in St. Louis, Saint Louis, MO, ⁶The BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI, ⁷Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, ⁸The Christie NHS Foundation Trust, Manchester Cancer Research Centre and Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁹BMT Group of Georgia, BMT Group of Georgia, Atlanta, GA, ¹⁰Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹¹Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, ¹²Division of Hematology & Oncology, Department of Internal Medicine, University of Nebraska Medical Center- Fred and Pamela Buffett Cancer Center, Omaha, NE, ¹³IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seragnoli" Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy, ¹⁴Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, Switzerland, ¹⁵Humanitas University and IRCCS Humanitas Research Hospital, Milan, Milano, Italy, ¹⁶ADC Therapeutics America, Murray Hill, NJ, ¹⁷Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH, ¹⁸Taussig Cancer Institute, Cleveland Clinic, Cleveland, ¹⁹University of Miami, Miami, FL, ²⁰Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, ²¹Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, Miami, ²²Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL

2022 ASH Annual Meeting
Northside Blood and Marrow/Leukemia /Immunotherapy Program and Collaborative Oral and Poster Presentations

Collaborative Post Presentations: con't

3442 Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers

Tania Jain, MD¹, Hua-Ling Tsai, ScM², Hany Elmariah, MD, MS³, Pankit Vachhani, MD⁴, Theodoros Karantanos, MD, PhD⁵, Sarah A Wall, MD, MPH⁶, Lukasz P. Gondek, MD, PhD⁷, **Asad Bashey, MD, PhD⁸**, Alla Keyzner, MD⁹, Michael R. Grunwald, MD¹⁰, Sameem Abedin, MD¹¹, Kalyan VG Nadiminti, MD¹², Madiha Iqbal, MD¹³, Aaron T. Gerds, MD, MS¹⁴, Auro Viswabandya, MD, DM¹⁵, Shannon R McCurdy, MD¹⁶, MHD Monzr M. Al Malki, MD¹⁷, Ravi Varadhan, PhD², Haris Ali, MD¹⁸, Vikas Gupta, MD, FRCP, FRCPath¹⁹, Richard J. Jones, MD¹ and Salman Otoukesh, MD²⁰

¹Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, ²Oncology Biostatistics and Bioinformatics, Johns Hopkins University, Baltimore, MD, ³Moffitt Cancer Center, Tampa, FL ⁴O'Neal Comprehensive Cancer Center at UAB, Birmingham, AL, ⁵Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, ⁶Division of Hematology, The Ohio State University, Columbus, OH ⁷Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, ⁸BMT Group of Georgia, Atlanta, GA, ⁹Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, ¹¹Medical College of Wisconsin, Milwaukee, WI, ¹²University of Wisconsin Hospital, Madison, WI, ¹³Mayo Clinic, Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Jacksonville, FL, ¹⁴Department of Hematology and Medical Oncology,, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, ¹⁵Hans Messner Allogeneic Blood and Marrow Transplant Unit, Princess Margaret Cancer Centre, Toronto, Canada ¹⁶University of Pennsylvania, Philadelphia, PA, ¹⁷Department of Hematology/HCT, City of Hope, Duarte, CA ¹⁸City of Hope Medical Center, Duarte, CA, ¹⁹Division of Medical Oncology and Hematology, University Health Network, Toronto, ON, Canada, ²⁰Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA

2022 ASH Annual Meeting
Northside Blood and Marrow/Leukemia /Immunotherapy Program and Collaborative Oral and Poster Presentations

Collaborative Poster Presentations: con't

4252 A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

Tamer Othman, MD¹, Christopher Ruel², Paul Frankel, PhD², Alexander A. Merleev, PhD¹, Guillaume Luxardi, PhD¹, Emanuel Maverakis, MD¹, Mehrdad Abedi, MD¹, Raghuv eer Ranganathan, MD³, Jasmine Zain, MD², Lihua E Budde, MD, PhD², Matthew Mei, MD², Aaron S Rosenberg, MD¹, Rasmus T Hoeg, MD¹, Caitlin Costello, MD⁴, Francine M. Foss, MD⁵, Basem M. William, MRCP, MD⁶, **H. Kent Holland, MD⁷**, Miguel Villalona-Calero, MD², Elad Sharon, MD, MPH⁸ and Joseph M Tuscano, MD¹

¹University of California Davis Comprehensive Cancer Center, Sacramento, CA,,²City of Hope, Duarte, CA

³Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA,⁴Moore's Cancer Center, University of California San Diego, La Jolla, CA, ⁵Hematology, Yale Cancer Center, New Haven, CT

⁶The James Cancer Center, Ohio State University, Columbus, OH, ⁷Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA,⁸Division of Cancer Treatment and Diagnosis, National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD